Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Carboplatin
100%
Ovarian Carcinoma
100%
ABT-737
100%
Combination Therapy
50%
Bcl-xL
50%
Ovarian Cancer
16%
Novel Therapeutics
16%
Xenograft
16%
Model Validation
16%
Chemotherapy
16%
Small Molecule Inhibitors
16%
Mathematical Model
16%
Drug Delivery
16%
DNA Repair
16%
Treatment Outcome
16%
Chemotherapy Resistance
16%
Residual Disease
16%
Recurrent Disease
16%
Drug Loading
16%
Bolus Dose
16%
Anti-apoptotic Proteins
16%
Disease-free Survival
16%
Resistant Cells
16%
Dosing Strategy
16%
Tumor Growth Inhibition
16%
Tumor Xenograft
16%
Infusion Duration
16%
Tumor Regression
16%
Survival Period
16%
Platinum Drugs
16%
Intrinsic Resistance
16%
Concurrent Inhibition
16%
BH3 Mimetics
16%
Carboplatin Resistance
16%
Periodic Schedules
16%
Delivery Schedule
16%
Tumor Remission
16%
Platinum Drug Resistance
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
100%
Carboplatin
100%
Combination Therapy
42%
Tumor Regression
28%
Platinum
28%
Antiapoptotic
14%
Intrinsic Resistance
14%
Chemotherapy Regimens
14%
Cancer Inhibition
14%
Survival Time
14%
Recurrent Disease
14%
Disease Free Survival
14%
Neoplasm
14%
Drug Resistance
14%
Minimal Residual Disease
14%
Low Drug Dose
14%
Neuroscience
Carboplatin
100%
In Vivo
14%
Chemotherapy
14%
DNA Repair
14%
Drug Resistance
14%